Summary by Moomoo AI
Biora Therapeutics, Inc. has filed a prospectus supplement on April 2, 2024, which updates and amends information from the original prospectus dated August 6, 2021, and the subsequent supplement dated November 6, 2022. The supplement pertains to the offering and sale of 1,300,250 shares of common stock, including shares issuable upon the exercise of warrants for up to 800,000 shares. The exercise price of these warrants was adjusted from $0.3288 to $8.22 following a reverse stock split in January 2023. On March 31, 2024, Biora Therapeutics entered into a Warrant Amendment Agreement with an institutional investor to further amend these warrants. The amendments include a reduction in the exercise price to $1.10 per share, a condition that the warrants will not be exercisable until stockholder approval is received, and an extension of the expiration date to five years post-approval. The company's common stock is traded on the Nasdaq Global Market under the symbol 'BIOR', with a last reported sale price of $1.10 per share as of March 28, 2024.